PBK and lung carcinoma: Kar et al. (2019) reported that PBK was overexpressed in ACC samples and correlated with poor survival, and targeting PBK in ACC cell lines decreased the function of cell proliferation, clonogenicity, and anchorage-independent growth. Diao et al. (2019) reported that the employment of a PBK/TOPK inhibitor could inhibit the proliferation of lung cancer cells. PBK also elevates in breast cancer and serves as a downstream target of Hippo-YAP signaling and promotes the proliferation of breast cancer cells by mediating the geranylgeranylation signaling pathway (Dou et al., 2015).